Immunocore publishes corporate presentation on bispecific soluble TCR platform and pipeline across oncology, infectious and autoimmune diseases

• Immunocore highlighted KIMMTRAK as the standard of care in first-line metastatic uveal melanoma, reporting USD 223 million net sales in 1H 2026.
• Reported 16% year-over-year growth, citing USD 116 million net sales in Q2 2026.
• Commercial footprint expanded to more than 30 launched markets, with penetration of at least 70% across major launched markets.
• Pipeline focus centered on late-stage melanoma studies, with TEBE-AM enrollment nearing 540 patients, topline data as early as end-2026.
• Adjuvant uveal melanoma Phase 3 ATOM trial outlined at about 290 HLA-A02:01 patients, with primary endpoint relapse-free survival.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.